{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:54:53Z","timestamp":1777586093497,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03164-0","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T20:36:34Z","timestamp":1744144594000},"page":"2767-2781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2\u2013, Node-Positive, High-Risk Early Breast Cancer"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2256-8919","authenticated-orcid":false,"given":"Alison","family":"Davie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sory","family":"Traor\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Badreldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Torstensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"Cakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuja C.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Tempelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"6","key":"3164_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1586\/14737167.2014.949243","volume":"14","author":"S Gupta","year":"2014","unstructured":"Gupta S, Zhang J, Jerusalem G. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):929\u201340.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3164_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.breast.2018.03.004","volume":"39","author":"L Wang","year":"2018","unstructured":"Wang L, et al. Health-related quality of life and utility scores of patients with breast neoplasms in China: a multicenter cross-sectional survey. Breast. 2018;39:53\u201362.","journal-title":"Breast"},{"key":"3164_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12885-015-1762-3","volume":"15","author":"G Jerusalem","year":"2015","unstructured":"Jerusalem G, et al. Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. BMC Cancer. 2015;15:787.","journal-title":"BMC Cancer"},{"issue":"1","key":"3164_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12955-018-0965-0","volume":"16","author":"J Yu","year":"2018","unstructured":"Yu J, et al. Uneven recovery patterns of compromised health-related quality of life (EQ-5D-3 L) domains for breast cancer survivors: a comparative study. Health Qual Life Outcomes. 2018;16(1):143.","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"3164_CR5","first-page":"688","volume":"26","author":"E Lim","year":"2012","unstructured":"Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688\u201396.","journal-title":"Oncology (Williston Park)"},{"issue":"34","key":"3164_CR6","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SR Johnston","year":"2020","unstructured":"Johnston SR, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"J Clin Oncol"},{"key":"3164_CR7","doi-asserted-by":"crossref","unstructured":"Rastogi P, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor\u2013positive, Human epidermal growth factor receptor 2\u2013negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024. p. JCO. 23.01994.","DOI":"10.1200\/JCO.23.01994"},{"key":"3164_CR8","unstructured":"National Institute for Health and Care Excellence, NICE Process and Methods Guides, in Guide to the Methods of Technology Appraisal 2013. (2013) National Institute for Health and Care Excellence (NICE), London"},{"issue":"1","key":"3164_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9\u201317.","journal-title":"Value Health"},{"issue":"1","key":"3164_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, CHEERS 2022 ISPOR Good Research Practices Task Force, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health."},{"issue":"1","key":"3164_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10\u201331.","journal-title":"Value Health"},{"issue":"1","key":"3164_CR12","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1093\/oncolo\/oyac234","volume":"28","author":"M Toi","year":"2023","unstructured":"Toi M, et al. Adjuvant abemaciclib combined with endocrine therapy: efficacy results in monarchE cohort 1. Oncologist. 2023;28(1):e77\u201381.","journal-title":"Oncologist"},{"issue":"12","key":"3164_CR13","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","journal-title":"Ann Oncol"},{"key":"3164_CR14","unstructured":"National Institute for Health and Care Excellence, Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [Technology appraisal guidance TA725]. 2021."},{"key":"3164_CR15","unstructured":"National Institute for Health and Care Excellence, Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [Technology appraisal guidance TA563]. 2019."},{"key":"3164_CR16","unstructured":"Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. 2011(0)."},{"key":"3164_CR17","unstructured":"Eli Lilly and Company, Abemaciclib monarchE SLR. Internal data on file. October 2021."},{"issue":"12","key":"3164_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135\u201341.","journal-title":"Lancet Oncol"},{"issue":"9","key":"3164_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, et al. Annual Hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927\u201335.","journal-title":"J Clin Oncol"},{"key":"3164_CR20","unstructured":"National Institute for Health and Care Excellence, Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab [Technology appraisal guidance TA612]. 2019."},{"key":"3164_CR21","unstructured":"National Institute for Health and Care Excellence, Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [Technology appraisal guidance TA632]. 2020."},{"key":"3164_CR22","unstructured":"Jones K, Burns A. Unit Costs of Health and Social Care 2021. 2022 PSSRU, University of Kent."},{"key":"3164_CR23","unstructured":"NHS improvements, National schedule of reference costs\u2014year 2021\/2022\u2014NHS trust and NHS foundation trusts. 2023."},{"key":"3164_CR24","unstructured":"Jones K, et al. Unit Costs of Health and Social Care 2022 Manual. 2023. Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York)."},{"key":"3164_CR25","unstructured":"Department of Health and Social Care, Drugs and pharmaceutical electronic market information tool (eMIT)."},{"key":"3164_CR26","unstructured":"National Institute for Health Care Excellence. BNF. 2023 October 2023]; Available from: https:\/\/bnf.nice.org.uk\/drugs\/ranibizumab-specialist-drug\/medicinal-forms\/."},{"key":"3164_CR27","unstructured":"National Institute for Health and Care Excellence, Pertuzumab for adjuvant treatment of HER2-positive early-stage breast cancer [Technology appraisal guidance TA569]. 2019."},{"key":"3164_CR28","unstructured":"National Institute for Health and Care Excellence, Early and locally advanced breast cancer: diagnosis and management | NICE guideline NG101 | Evidence reviews. 2018."},{"key":"3164_CR29","unstructured":"National Institute for Health Care Excellence, Advanced breast cancer: diagnosis and treatment Clinical guideline [CG81]. 2017."},{"issue":"1","key":"3164_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3164_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"issue":"4","key":"3164_CR32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","volume":"14","author":"R Ara","year":"2011","unstructured":"Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539\u201345.","journal-title":"Value Health"},{"issue":"5","key":"3164_CR33","first-page":"39","volume":"2","author":"A Stacie Hudgens","year":"2016","unstructured":"Stacie Hudgens A, et al. A method of deriving estimates of health state utilities for patients with metastatic breast cancer. J Clin Pathways. 2016;2(5):39\u201345.","journal-title":"J Clin Pathways"},{"key":"3164_CR34","unstructured":"National Institute for Health and Care Excellence, Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin\u2019s Bcell lymphoma Technology appraisal guidance [TA306]. 2014."},{"key":"3164_CR35","unstructured":"National Institute for Health and Care Excellence, Idelalisib for treating chronic lymphocytic leukaemia Technology appraisal guidance [TA359]. 2015."},{"key":"3164_CR36","unstructured":"National Institute for Health and Care Excellence, Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer Technology appraisal guidance [TA503]. 2018."},{"key":"3164_CR37","unstructured":"National Institute for Health and Care Excellence, Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Technology appraisal guidance [TA579]. 2019."},{"key":"3164_CR38","unstructured":"England N, National Cancer Drugs Fund list\u2014version 1.311. 2024."},{"issue":"7","key":"3164_CR39","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40273-023-01259-6","volume":"41","author":"G Orozco Leal","year":"2023","unstructured":"Orozco Leal G, et al. Abemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2023;41(7):741\u201350.","journal-title":"Pharmacoeconomics"},{"key":"3164_CR40","unstructured":"National Institute for Health and Care Excellence, Technology appraisal guidance [TA810]: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. 2022."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03164-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03164-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03164-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:00:34Z","timestamp":1747468834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03164-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3164"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03164-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alison Davie, Sory Traor\u00e9, Waleed Badreldin and Astrid Torstensson are all employees of Eli Lilly and Company. Peter S Hall has disclosed an advisory role with Eli Lilly and Company Ltd.; for which an honorarium was received for consultancy in the development of this study. Esra Cakar and Anuja C. McCullough were employees of OPEN Health HEOR & Market Access at the time that the work was undertaken. Esra Cakar is now an employee of Pfizer. Anuja C. McCullough is now an employee of the National Institute for Health and Care Excellence. Susan Tempelaar and Elisabeth Fenwick are employees of OPEN Health HEOR & Market Access. OPEN Health HEOR & Market Access received funding from Eli Lilly and Company Ltd. for consultancy and study development.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was based on a previously conducted randomized, open-label phase 3 study and does not contain any new data evaluating human participants or animals. Eli Lilly and Company Ltd. approve the use of these data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}